Compare FUBO & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FUBO | PROF |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Broadcasting | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 284.3M | 238.1M |
| IPO Year | 2011 | 2017 |
| Metric | FUBO | PROF |
|---|---|---|
| Price | $11.53 | $6.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $28.40 | $12.00 |
| AVG Volume (30 Days) | ★ 2.4M | 100.4K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.08 | 25.89 |
| EPS | N/A | ★ 1.41 |
| Revenue | $4,271,000.00 | ★ $16,098,000.00 |
| Revenue This Year | $44.64 | $92.40 |
| Revenue Next Year | $5.62 | $64.10 |
| P/E Ratio | ★ N/A | $4.99 |
| Revenue Growth | ★ 10317.07 | 50.73 |
| 52 Week Low | $1.02 | $3.92 |
| 52 Week High | $14.54 | $8.95 |
| Indicator | FUBO | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 59.73 | 54.08 |
| Support Level | $3.17 | $5.75 |
| Resistance Level | $14.05 | $7.07 |
| Average True Range (ATR) | 0.95 | 0.42 |
| MACD | -0.41 | 0.05 |
| Stochastic Oscillator | 15.32 | 65.83 |
FuboTV Inc is a sports-first, live TV streaming company offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, FuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. It offers subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality suited to their preferences. The company has one operating segment, the streaming business. Geographically, the company generates a majority of its revenue from the United States and also has a presence in other markets.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.